View ValuationPharmanutra 향후 성장Future 기준 점검 4/6Pharmanutra (는) 각각 연간 19.8% 및 11.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31.9% 로 예상됩니다.핵심 정보19.8%이익 성장률19.49%EPS 성장률Personal Products 이익 성장8.0%매출 성장률11.1%향후 자기자본이익률31.86%애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.공시 • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.공시 • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.공시 • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025공시 • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.공시 • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024Board Change • Jun 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the United Kingdom.Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (1.8%).Board Change • Apr 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 19Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Personal Products industry in the United Kingdom.Board Change • Feb 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023Board Change • Dec 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Dec 07Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract to acquire Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. As of year ended 2021, Akern s.r.l. reported revenue of €4.2 million, EBITDA of €1.2 million and net income of €0.58 million. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. As of July 26, 2022, Pharmanutra acquired 72.96% stake in Akern from Red Lions. Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri on December 5, 2022.Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 16Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom.Board Change • Aug 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jun 16Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • May 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Feb 15PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel FoodPharmaNutra S.p.A. announced that the European Union had published a notice in the Official Gazette authorising the marketing of cetylated fatty acids as a Novel Food. The novel food (Lipocet®) is a combination of myristic acid and oleic acid and, to a lesser degree, other cetylated fatty acids, which until now could be used only in Cetilar®-branded products for topical use. Consequently, PharmaNutra's patented cetylated fatty acids will be included in the EU list of authorised novel foods established in implementing regulation (EU) 2017/2470. The inclusion of the CFAs in the list marks the official completion of the registration procedure under which, in July 2021, the European Food Safety Authority (EFSA) formalised its positive opinion on the safety of CFAs. The Novel Food authorisation is a fundamental new strategic asset for the Group, as it will enable new nutritional supplements based on CFAs to be developed and marketed. The authorisation also provides a protection for industrial property, giving PharmaNutra exclusive right of use for five-year of the new ingredient throughout the European Union.Board Change • Dec 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측BATS-CHIXE:PHNM - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028204363339312/31/2027181312836312/31/202615525222933/31/2026139211619N/A12/31/2025132201620N/A9/30/2025127171014N/A6/30/202512217812N/A3/31/2025119162125N/A12/31/2024116171620N/A9/30/2024113161923N/A6/30/2024108141520N/A3/31/202410111212N/A12/31/202310113-112N/A9/30/20239512-512N/A6/30/20239314-1912N/A3/31/20238816-1514N/A12/31/20228315-917N/A9/30/20227916-519N/A6/30/202276151019N/A3/31/202273151420N/A12/31/202168141520N/A9/30/202165141316N/A6/30/202160111215N/A3/31/202157141315N/A12/31/202057141012N/A9/30/202058141111N/A6/30/20205814711N/A3/31/202055949N/A12/31/2019548N/A12N/A9/30/2019498N/A8N/A6/30/2019509N/A9N/A3/31/2019489N/A8N/A12/31/2018479N/A6N/A9/30/2018448N/A6N/A6/30/2018417N/A6N/A3/31/2018406N/A6N/A12/31/2017386N/A6N/A9/30/2017375N/AN/AN/A6/30/2017355N/AN/AN/A3/31/2017344N/AN/AN/A12/31/2016334N/A6N/A12/31/2015263N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PHNM 의 연간 예상 수익 증가율(19.8%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: PHNM 의 연간 수익(19.8%)이 UK 시장(11.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: PHNM 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: PHNM 의 수익(연간 11.1%)이 UK 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PHNM 의 수익(연간 11.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PHNM의 자본 수익률은 3년 후 31.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHousehold 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/18 18:56종가2026/05/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmanutra S.p.A.는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Anna FrontaniBerenbergAndrea RandoneIntermonte SIM S.p.A.Giorgio TavoliniIntermonte SIM S.p.A.3명의 분석가 더 보기
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
공시 • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.
공시 • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
공시 • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.
공시 • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
공시 • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.
공시 • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024
Board Change • Jun 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the United Kingdom.
Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (1.8%).
Board Change • Apr 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 19Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Personal Products industry in the United Kingdom.
Board Change • Feb 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023
Board Change • Dec 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Dec 07Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract to acquire Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. As of year ended 2021, Akern s.r.l. reported revenue of €4.2 million, EBITDA of €1.2 million and net income of €0.58 million. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. As of July 26, 2022, Pharmanutra acquired 72.96% stake in Akern from Red Lions. Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri on December 5, 2022.
Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 16Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom.
Board Change • Aug 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jun 16Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • May 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Feb 15PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel FoodPharmaNutra S.p.A. announced that the European Union had published a notice in the Official Gazette authorising the marketing of cetylated fatty acids as a Novel Food. The novel food (Lipocet®) is a combination of myristic acid and oleic acid and, to a lesser degree, other cetylated fatty acids, which until now could be used only in Cetilar®-branded products for topical use. Consequently, PharmaNutra's patented cetylated fatty acids will be included in the EU list of authorised novel foods established in implementing regulation (EU) 2017/2470. The inclusion of the CFAs in the list marks the official completion of the registration procedure under which, in July 2021, the European Food Safety Authority (EFSA) formalised its positive opinion on the safety of CFAs. The Novel Food authorisation is a fundamental new strategic asset for the Group, as it will enable new nutritional supplements based on CFAs to be developed and marketed. The authorisation also provides a protection for industrial property, giving PharmaNutra exclusive right of use for five-year of the new ingredient throughout the European Union.
Board Change • Dec 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.